[go: up one dir, main page]

WO2011014825A3 - Petites molécules anti-angiogéniques et procédés d'utilisation - Google Patents

Petites molécules anti-angiogéniques et procédés d'utilisation Download PDF

Info

Publication number
WO2011014825A3
WO2011014825A3 PCT/US2010/043998 US2010043998W WO2011014825A3 WO 2011014825 A3 WO2011014825 A3 WO 2011014825A3 US 2010043998 W US2010043998 W US 2010043998W WO 2011014825 A3 WO2011014825 A3 WO 2011014825A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
small molecules
antiangiogenic small
antiangiogenic
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/043998
Other languages
English (en)
Other versions
WO2011014825A2 (fr
Inventor
Enrique Zudaire
Marta Aparicio
Frank Cuttitta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Priority to US13/387,969 priority Critical patent/US9186365B2/en
Priority to AU2010278738A priority patent/AU2010278738A1/en
Priority to JP2012523106A priority patent/JP5886743B2/ja
Priority to CA2769038A priority patent/CA2769038A1/fr
Priority to EP20100805140 priority patent/EP2461806A4/fr
Publication of WO2011014825A2 publication Critical patent/WO2011014825A2/fr
Publication of WO2011014825A3 publication Critical patent/WO2011014825A3/fr
Anticipated expiration legal-status Critical
Priority to US14/882,271 priority patent/US9504729B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/285—Arsenic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des procédés permettant d'inhiber une angiogenèse non souhaitée, lesdits procédés consistant à administrer à un patient une quantité thérapeutiquement efficace d'au moins un des composés décrits ici, ou son sel pharmaceutiquement acceptable.
PCT/US2010/043998 2009-07-31 2010-07-30 Petites molécules anti-angiogéniques et procédés d’utilisation Ceased WO2011014825A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US13/387,969 US9186365B2 (en) 2009-07-31 2010-07-30 Antiangiogenic small molecules and methods of use
AU2010278738A AU2010278738A1 (en) 2009-07-31 2010-07-30 Antiangiogenic small molecules and methods of use
JP2012523106A JP5886743B2 (ja) 2009-07-31 2010-07-30 抗血管新生性低分子および使用方法
CA2769038A CA2769038A1 (fr) 2009-07-31 2010-07-30 Petites molecules anti-angiogeniques et procedes d'utilisation
EP20100805140 EP2461806A4 (fr) 2009-07-31 2010-07-30 Petites molécules anti-angiogéniques et procédés d utilisation
US14/882,271 US9504729B2 (en) 2009-07-31 2015-10-13 Antiangiogenic small molecules and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23066709P 2009-07-31 2009-07-31
US61/230,667 2009-07-31

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/387,969 A-371-Of-International US9186365B2 (en) 2009-07-31 2010-07-30 Antiangiogenic small molecules and methods of use
US14/882,271 Division US9504729B2 (en) 2009-07-31 2015-10-13 Antiangiogenic small molecules and methods of use

Publications (2)

Publication Number Publication Date
WO2011014825A2 WO2011014825A2 (fr) 2011-02-03
WO2011014825A3 true WO2011014825A3 (fr) 2011-06-16

Family

ID=43529970

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/043998 Ceased WO2011014825A2 (fr) 2009-07-31 2010-07-30 Petites molécules anti-angiogéniques et procédés d’utilisation

Country Status (6)

Country Link
US (2) US9186365B2 (fr)
EP (1) EP2461806A4 (fr)
JP (3) JP5886743B2 (fr)
AU (1) AU2010278738A1 (fr)
CA (1) CA2769038A1 (fr)
WO (1) WO2011014825A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012145575A2 (fr) * 2011-04-21 2012-10-26 Children's Hospital Medical Center Thérapie pour la leucémie
US10342767B2 (en) 2011-04-21 2019-07-09 Children's Hospital Medical Center Therapy for kinase-dependent malignancies
CA2865675C (fr) 2012-02-27 2023-02-28 Steven J.M. JONES Reprogrammation d'interactions entre proteines effectrices pour corriger des defauts epigenetiques dans le cancer
FR3003581B1 (fr) 2013-03-20 2015-03-20 Ahlstroem Oy Support fibreux a base de fibres et de nanofibrilles de polysaccharide
KR20150139569A (ko) 2013-04-02 2015-12-11 유니버시티 오브 플로리다 리서치 파운데이션, 인크. 혈관형성의 유도 및 조절을 위한 조성물 및 방법 및 혈관형성 조절 인자를 확인하기 위한 방법 및 분석법
WO2015033228A2 (fr) * 2013-09-09 2015-03-12 Glionova Ab Composés et leur utilisation pour le traitement du cancer
WO2015188130A1 (fr) * 2014-06-05 2015-12-10 The University Of Kansas Analogues du marmelin et méthodes d'utilisation dans le traitement du cancer
EP3064205A1 (fr) * 2015-03-06 2016-09-07 Glionova AB Utilisation thérapeutique de formes isomères de 2-(4-chlorophényl) quinoline-4-yl) (pipéridine-2-yl)méthanol
WO2016196742A1 (fr) * 2015-06-03 2016-12-08 Du-Shieng Chien Nouvelle utilisation de dérivés aryl-quinoléine comme inhibiteurs de l'imitation de facteurs vasculogènes
EP3323428A1 (fr) * 2016-11-17 2018-05-23 CNRS Centre National de la Recherche Scientifique Inhibiteurs sélectifs de c-flip en tant qu'agents anticancéreux
WO2019241802A2 (fr) * 2018-06-15 2019-12-19 Ideaya Biosciences, Inc. Procédés d'inhibition de cellules prolifératives
JP2023504573A (ja) * 2019-12-09 2023-02-03 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 造血幹細胞を生成するための方法
IT202000006931A1 (it) * 2020-04-02 2021-10-02 Orpha Biotech S R L INIBITORI DELL’INTERAZIONE DEI RECETTORI uPAR/FPRs
CN119236082A (zh) * 2024-10-16 2025-01-03 遵义医科大学附属医院 Mapk4激动剂在制备类风湿性关节炎药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0011277A1 (fr) * 1978-11-14 1980-05-28 Takeda Chemical Industries, Ltd. Déchloromaytansinoides, leur préparation et utilisation et compositions pharmaceutiques les contenant
US6756388B1 (en) * 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
EP1583522B1 (fr) * 2003-01-15 2008-10-08 Forskarpatent i Syd AB Utilisation d'inhibiteurs de la cycline d1 pour le traitement du cancer du sein
EP1319000B1 (fr) * 2000-09-20 2008-11-05 Aprea Ab Utilisation de derives de 1-azabicyclo(2.2.2)octan-3-one pour traiter des tumeurs cancereuses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56102793A (en) * 1979-12-28 1981-08-17 Takeda Chem Ind Ltd Preparation of antibiotic c-15003 p-3
HUP0102492A2 (hu) * 1998-06-19 2001-11-28 Smithkline Beecham Corp. Amino-indanon származékok alkalmazása NF-kB transzkripciós faktor inhibitor hatású gyógyszerkészítmények előállítására
WO2008027912A2 (fr) * 2006-08-28 2008-03-06 Dan Theodorescu Prédiction de l'activité d'agents sur différents types de cellules et de tissus
US8679836B2 (en) 2007-10-01 2014-03-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of monitoring angiogenesis and metastasis in three dimensional co-cultures
US20110110886A1 (en) * 2008-06-13 2011-05-12 Yale University Small molecule inhibitors of autotaxin and methods of use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0011277A1 (fr) * 1978-11-14 1980-05-28 Takeda Chemical Industries, Ltd. Déchloromaytansinoides, leur préparation et utilisation et compositions pharmaceutiques les contenant
US6756388B1 (en) * 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
EP1319000B1 (fr) * 2000-09-20 2008-11-05 Aprea Ab Utilisation de derives de 1-azabicyclo(2.2.2)octan-3-one pour traiter des tumeurs cancereuses
EP1583522B1 (fr) * 2003-01-15 2008-10-08 Forskarpatent i Syd AB Utilisation d'inhibiteurs de la cycline d1 pour le traitement du cancer du sein

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2461806A4 *

Also Published As

Publication number Publication date
JP5886743B2 (ja) 2016-03-16
WO2011014825A2 (fr) 2011-02-03
JP6023143B2 (ja) 2016-11-09
EP2461806A2 (fr) 2012-06-13
US20120129775A1 (en) 2012-05-24
CA2769038A1 (fr) 2011-02-03
AU2010278738A1 (en) 2012-02-16
JP2017014276A (ja) 2017-01-19
US20160030508A1 (en) 2016-02-04
US9504729B2 (en) 2016-11-29
EP2461806A4 (fr) 2012-12-26
US9186365B2 (en) 2015-11-17
JP2015038122A (ja) 2015-02-26
JP2013501004A (ja) 2013-01-10

Similar Documents

Publication Publication Date Title
WO2011014825A3 (fr) Petites molécules anti-angiogéniques et procédés d'utilisation
WO2011055944A3 (fr) Procédés pour traiter un syndrome de fibromyalgie
WO2009017837A3 (fr) Aérosol sublingual de fentanyl
IL250439A0 (en) Use of fingolimod, or a phosphate derivative thereof or a pharmaceutical acceptable salt thereof for the preparation of a drug for the treatment of multiple sclerosis
HK1211475A1 (en) Combination therapy
GEP20125624B (en) Pyridazine derivatives as smo inhibitors
AP2010005508A0 (en) Triazole derivatives useful for the treatment of diseases.
PT2515886T (pt) Sistema terapêutico transdermal para a administração de rivastigmina ou de seus derivados
WO2009089494A3 (fr) Compositions pharmaceutiques
WO2012019426A8 (fr) Dérivé de phtalazinone, son procédé de préparation et utilisation pharmaceutique
WO2011009938A3 (fr) Stambomycine et dérivés, leur production et leur utilisation comme médicaments
WO2009091898A3 (fr) Composés de 6-aminoisoquinoléine et 7-aminoisoquinoléine et leurs procédés de fabrication et d'utilisation
WO2008070268A3 (fr) Compositions pharmaceutiques
WO2012019430A8 (fr) Dérivé de phtalazinone, son procédé de préparation et utilisation pharmaceutique
CA2770066C (fr) Prostacycline, analogue ou derive de celui-ci pour le traitement de la fibrose kystique
WO2012051559A3 (fr) Compositions et méthodes de traitement de l'hypertension artérielle pulmonaire
WO2012040636A3 (fr) Composés et méthodes de traitement de maladies à médiation par des récepteurs activés par une protéase
WO2012118308A3 (fr) Composition contenant un dérivé de pyrazole destinée à prévenir et à traiter les maladies cardiovasculaires
WO2012002687A3 (fr) Procédés de traitement du trouble bipolaire
WO2013003669A3 (fr) Compositions, méthodes d'utilisation et méthodes de traitement
IL214133A (en) Isolated or cleaned Inganol or its pharmacist salt for skin care
AP2012006292A0 (en) Topical use of hydroxytyrosol and derivatives for the prevention of HIV infection.
PL2196206T3 (pl) Środek do łagodzenia problemów skórnych zawierający pochodną morfinanu lub jego farmakologicznie dopuszczalną kwasową sól addycyjną jako substancję czynną
WO2008129501A3 (fr) Compositions pharmaceutiques de duloxetine
WO2010012459A3 (fr) Procédé de préparation de sels de solifénacine et inclusion de ces derniers dans des formes pharmaceutiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10805140

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2769038

Country of ref document: CA

Ref document number: 2010278738

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 13387969

Country of ref document: US

Ref document number: 2012523106

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2010278738

Country of ref document: AU

Date of ref document: 20100730

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010805140

Country of ref document: EP